Recent Updates
Recently added Catalysts

Vonsetamig

Phase 1

Chronic Kidney Disease (CKD) | Small molecule | Nephrology |Regeneron Pharmaceuticals, Inc.|Last Updated: Jul 9, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment43
FDA Designations
No designations recorded
Clinical trial landscape

Vonsetamig · 2 trials · 2 indications

Phase 1 2
NCT06975787Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisLupus Nephritis (LN)
RECRUITING90 Analytics
NCT05092347A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)Chronic Kidney Disease (CKD)
ACTIVE NOT_RECRUITING43 Analytics
PHASE1RECRUITING
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Lupus Nephritis (LN)
NCT0697578790
Unlock trial analytics
PHASE1ACTIVE NOT_RECRUITING
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Chronic Kidney Disease (CKD)
NCT0509234743
Unlock trial analytics
Study Endpoints
Primary Endpoints
Occurrence of Dose Limiting Toxicities (DLT)
Up to 56 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Through week 76
Severity of TEAEs
Through week 76
Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period
Up to approximately 6 weeks
Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the study
Up to 78 weeks

TEAEs include adverse events of special interest (AESI) and serious adverse events (SAEs)

Secondary Endpoints
Proportion of participants no longer receiving a corticosteroid
At 6 months
Cumulative total exposure to corticosteroids
At 76 weeks
Absolute values of urine Protein-Creatinine Ratio (uPCR)
Through week 76
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Experimental Arm 1: VonsetamigEXPERIMENTAL -
Experimental Arm 2: OdronextamabEXPERIMENTAL -
VonsetamigEXPERIMENTAL -
Interventions
NameTypeDescription
VonsetamigDRUGAdministered as per the protocol
OdronextamabDRUGAdministered as per the protocol
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites18

Key General Inclusion Criteria: 1. Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol 2. Participant must have refractory or relapsed disease, as described in the protocol Key General Exclusion Criteria: 1. History of or active severe or unstable lupus-associated...

Countries:United StatesFranceGermanySouth KoreaSpainTaiwan
Unlock Eligibility Criteria
Competitive Landscape -Chronic Kidney Disease 91 trials (matched to "Chronic Kidney Disease (CKD)")

Top 20 of 26 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN12PHASE3Savolitinib, Sunitinib
Eli Lilly and CompanyLLY5PHASE3Retatrutide
Novo Nordisk A/S Sponsored ADR Class BNVO4PHASE3Ziltivekimab B, Ziltivekimab C
Fresenius Medical Care AG Sponsored ADRFMS8PHASE3Dialysis
Novartis AG Sponsored ADRNVS4PHASE3zigakibart
Amgen Inc.AMGN1PHASE3Etelcalcetide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK2PHASE3Mezagitamab
ProKidney Corp. Class APROK3PHASE3Renal Autologous Cell Therapy
Humacyte, Inc.HUMA1PHASE3Acellular Tissue Engineered Vessel
DexCom, Inc.DXCM1PHASE3Sotagliflozin
GSK plc Sponsored ADRGSK1PHASE1GSK4771261
Regeneron Pharmaceuticals, Inc.REGN2PHASE1Vonsetamig
Merck & Co., Inc.MRK1PHASE1MK-2828
United Therapeutics CorporationUTHR2PHASE110 GE Xenokidney
Pfizer Inc.PFE1PHASE1PF-07328948
Atea Pharmaceuticals, Inc.AVIR1PHASE1Bemnifosbuvir /Ruzasvir as a fixed-dose combination
OPKO Health, Inc.OPK1PHASE2CTAP101
Medtronic PlcMDT2 - Undisclosed
Incyte CorporationINCY1PHASE1INCB123667
Merit Medical Systems, Inc.MMSI1 - Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJul 9, 2026NCT06975787lastUpdatePostDate: changed
LOWJul 9, 2026NCT06975787lastUpdatePostDate: changed
LOWJun 18, 2026NCT06975787lastUpdatePostDate: changed
LOWJun 18, 2026NCT06975787lastUpdatePostDate: changed
LOWJun 18, 2026NCT06975787lastUpdatePostDate: changed
LOWJun 18, 2026NCT06975787lastUpdatePostDate: changed
MEDIUMJun 8, 2026NCT06975787primaryCompletionDate: changed
MEDIUMJun 8, 2026NCT06975787primaryCompletionDate: changed
MEDIUMJun 8, 2026NCT06975787primaryCompletionDate: changed
HIGHJun 2, 2026NCT05092347Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHJun 2, 2026NCT05092347Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHJun 2, 2026NCT05092347Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMMay 26, 2026NCT05092347primaryCompletionDate: changed
LOWMay 26, 2026NCT06975787primaryCompletionDate: changed
LOWMay 24, 2026NCT05092347studyFirstPostDate: changed
LOWMay 24, 2026NCT06975787studyFirstPostDate: changed